Huang Cheng-Chieh, Chen Kuan-Wei, Twu Chih-Wen, Huang Hung-Meng, Hsu Hsin-Chien
Department of Otolaryngology Taipei City Hospital Taipei Taiwan.
Department of Otolaryngology Changhua Christian Hospital Changhua Taiwan.
Laryngoscope Investig Otolaryngol. 2022 Jan 6;7(1):12-21. doi: 10.1002/lio2.726. eCollection 2022 Feb.
To compare the effects of botulinum toxin and steroid septal injections in treating allergic rhinitis (AR) by evaluating improvements in the rhinitis control assessment test (RCAT), visual analog scale (VAS), nasal obstruction symptom evaluation (NOSE) scores, and active anterior rhinomanometry (RMM) measurements.
This prospective, single-blinded cohort study was conducted at the Department of Otolaryngology, Taipei City Hospital between January 2017 and December 2018. Ninety-five patients were randomized to receive botulinum toxin, dexamethasone, or normal saline (group A, group B, and placebo, respectively). The main outcome measures were pretreatment subjective nasal symptoms (RCAT, VAS, and NOSE) and active anterior RMM measurements. All measurements were repeated during posttreatment 1, 2, and 3 months.
No significant difference was observed in pretreatment questionnaire scores and RMM values between the study and placebo groups. The mean posttreatment RCAT, VAS, and NOSE scores after 1 and 2 months significantly improved in the treatment groups compared to placebo. The VAS and NOSE at posttreatment 2 months and RCAT, VAS, and NOSE at posttreatment 3 months were significantly different comparing group A to group B. All RMM parameters showed better values in group A than in group B at 1, 2, and 3 months posttreatment, with significant differences in four parameters in posttreatment 3 months.
Botulinum toxin septal injection is a safe treatment option for AR and improves subjective nasal symptoms for 3 months. Botulinum toxin A injection tended to be more effective than steroid septal injection in terms of duration and degree.Level of Evidence: 2b, individual cohort study.
通过评估鼻炎控制评估测试（RCAT）、视觉模拟量表（VAS）、鼻阻塞症状评估（NOSE）评分以及主动前鼻测压法（RMM）测量结果的改善情况，比较肉毒杆菌毒素和类固醇鼻中隔注射治疗变应性鼻炎（AR）的效果。
这项前瞻性、单盲队列研究于2017年1月至2018年12月在台北市立医院耳鼻喉科进行。95例患者被随机分为接受肉毒杆菌毒素、地塞米松或生理盐水治疗（分别为A组、B组和安慰剂组）。主要观察指标为治疗前主观鼻部症状（RCAT、VAS和NOSE）以及主动前鼻测压法测量结果。所有测量在治疗后1、2和3个月重复进行。
研究组与安慰剂组在治疗前问卷评分和RMM值方面未观察到显著差异。与安慰剂相比，治疗组在治疗后1个月和2个月时，平均RCAT、VAS和NOSE评分显著改善。比较A组和B组，治疗后2个月时的VAS和NOSE以及治疗后3个月时的RCAT、VAS和NOSE存在显著差异。在治疗后1、2和3个月时，所有RMM参数在A组中的值均优于B组，治疗后3个月时有四个参数存在显著差异。
肉毒杆菌毒素鼻中隔注射是治疗AR的一种安全选择，可改善主观鼻部症状达3个月。在持续时间和程度方面，A型肉毒杆菌毒素注射往往比类固醇鼻中隔注射更有效。证据级别：2b，个体队列研究。
